Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Steven Y. Hua"'
Autor:
Roy M. Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y. Hua, Carol Cronenberger, Daniel Alvarez, Amy E. Bock, K. Lea Sewell
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira®)
Externí odkaz:
https://doaj.org/article/1d4bd355220e4ba2b38cbe7e573f3370
Autor:
Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos, K. Lea Sewell
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-13 (2018)
Abstract Background This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), an infliximab biosimilar, vs infliximab (Rem
Externí odkaz:
https://doaj.org/article/467cbd7fd59e48078e3d671474187104
Autor:
Anthony W. Tolcher, Steven Pirie-Shepherd, Robert Wesolowski, Brenda Gibson, Lee S. Rosen, Steven Y. Hua, Kai-Hsin Liao, Raffaele Baffa
Publikováno v:
Investigational New Drugs. 38:120-130
Background PF-06650808 is a novel anti-Notch3 antibody–drug conjugate (ADC) able to deliver an auristatin-based cytotoxic payload to target cells. In this first-in-human, dose-finding, phase I study (NCT02129205), we investigated safety, pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a683116c97ca88234178e12efdc152ad
https://doi.org/10.1007/s10637-019-00754-y
https://doi.org/10.1007/s10637-019-00754-y
Autor:
Brian G. Feagan, Allan Olson, Silvio Danese, Geert R. D'Haens, Wenzhong J Liu, Steven Y. Hua, William J. Sandborn, Douglas C. Wolf, Neil Minton
Publikováno v:
lancet. Gastroenterology & hepatology, 5(9), 819-828. Elsevier Limited
Background: Although treatment of Crohn's disease has improved with development of tumour necrosis factor antagonists, fewer than 50% of patients have sustained benefit. Durable maintenance therapy with orally administered alternative treatments rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70854bfd8650504cdcb9b40cebd021be
https://pure.amc.nl/en/publications/ozanimod-induction-therapy-for-patients-with-moderate-to-severe-crohns-disease-a-singlearm-phase-2-prospective-observerblinded-endpoint-study(dcd92e58-3dfe-42e6-baf6-c305c3a1fe42).html
https://pure.amc.nl/en/publications/ozanimod-induction-therapy-for-patients-with-moderate-to-severe-crohns-disease-a-singlearm-phase-2-prospective-observerblinded-endpoint-study(dcd92e58-3dfe-42e6-baf6-c305c3a1fe42).html
Autor:
Sebastião Cezar Radominski, Karl Schumacher, Muhammad I. Rehman, Steven Y. Hua, Tomas Hala, Susanne Schmitt, K. Lea Sewell, Claudia Ianos, Rieke Alten, Ramesh Palaparthy, Stanley Cohen, Hideto Kameda
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-13 (2018)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), an infliximab biosimilar, vs infliximab (Remicade®)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbdfdab474b0654aea2dbb210a1a2639
http://link.springer.com/article/10.1186/s13075-018-1646-4
http://link.springer.com/article/10.1186/s13075-018-1646-4
Autor:
Ryan Deaton, Sarah Harris, Cristian Rodriguez, Steven Y. Hua, Ikuo Hirano, Margaret H. Collins, Evan S. Dellon, Peter H. Gann, Nathan McMahon
Publikováno v:
The Journal of allergy and clinical immunology. 146(2)
Background Fibrostenosis, the most serious eosinophilic esophagitis (EoE) complication, is mediated by epithelial-mesenchymal transition (EMT). Transitioned cells contribute to pathogenesis by overproducing extracellular matrix. Objective Our aim was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8042c8d8f7a1671e575718be74b37070
https://pubmed.ncbi.nlm.nih.gov/32407835
https://pubmed.ncbi.nlm.nih.gov/32407835
Autor:
Rieke Alten, K. Lea Sewell, Daniel F. Alvarez, Margarita Pileckyte, Amy E. Bock, Roy Fleischmann, Steven Y. Hua, Kasia Lobello, Carol Cronenberger
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira®) sourced f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e3e7916f3fae0f4b5d59489fc6f9c7
https://doi.org/10.1186/s13075-018-1676-y
https://doi.org/10.1186/s13075-018-1676-y
Autor:
Steven Y. Hua, Amy E. Bock, Roy Fleischmann, K.L. Sewell, Carol Cronenberger, Rieke Alten, Margarita Pileckyte
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background To confirm the efficacy, safety and immunogenicity of biosimilars, a comparative clinical study is typically required. Objectives This double-blind, randomised, 78 week (wk) study compared the efficacy, safety and immunogenicity of PF–06
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ef73ccdf10035b90ccb7f7fcd8b549d
https://doi.org/10.1136/annrheumdis-2018-eular.1359
https://doi.org/10.1136/annrheumdis-2018-eular.1359
Autor:
Gentry Teng King, Steven Y. Hua, Gilbert Y. Wong, Wells A. Messersmith, Heike Krupka, Brandon R. Beagle, Anthony B. El-Khoueiry, Keith D. Eaton, Christopher J. Zopf
Publikováno v:
Invest New Drugs
PURPOSE AND METHODS: Trop-2 is a glycoprotein over-expressed in many solid tumors but at low levels in normal human tissue, providing a potential therapeutic target. We conducted a phase 1 dose-finding study of PF-06664178, an antibody-drug conjugate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da4564124c58502e99627a04ecf4d06
https://europepmc.org/articles/PMC7519583/
https://europepmc.org/articles/PMC7519583/
Autor:
Ramesh Palaparthy, D. Yin, Muhammad I. Rehman, Joseph E. McClellan, Steven Y. Hua, Chandrasekhar Udata, Chun-Hua Cai, S. Salts, Xu Meng
Background: To demonstrate pharmacokinetic (PK) similarity of PF-06438179/GP1111, a potential biosimilar to Remicade®, to Remicade® sourced from European Union (infliximab-EU) and United States (infliximab-US), and of infliximab-EU to infliximab-US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815a133e2798e1511442ea5a6bd4f7eb